These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21807336)

  • 1. Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?
    Pharoah P; Antoniou A; Berchuck A; Chenevix-Trench G; Gayther S; Goode E; Milne R; Sellers T; Tyrer J
    Lancet Oncol; 2011 Aug; 12(8):723-4; author reply 724. PubMed ID: 21807336
    [No Abstract]   [Full Text] [Related]  

  • 2. KRAS 3'-UTR variants and stratification of breast-cancer risk.
    Kumar MS; Swanton C
    Lancet Oncol; 2011 Apr; 12(4):318-9. PubMed ID: 21435949
    [No Abstract]   [Full Text] [Related]  

  • 3. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
    Paranjape T; Heneghan H; Lindner R; Keane FK; Hoffman A; Hollestelle A; Dorairaj J; Geyda K; Pelletier C; Nallur S; Martens JW; Hooning MJ; Kerin M; Zelterman D; Zhu Y; Tuck D; Harris L; Miller N; Slack F; Weidhaas J
    Lancet Oncol; 2011 Apr; 12(4):377-86. PubMed ID: 21435948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
    Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB
    Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.
    Ryan BM; Robles AI; Harris CC
    Clin Cancer Res; 2012 Jun; 18(12):3487-8; author reply 3489. PubMed ID: 22669132
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
    Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
    Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
    Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
    Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
    Pharoah PD; Palmieri RT; Ramus SJ; Gayther SA; Andrulis IL; Anton-Culver H; Antonenkova N; Antoniou AC; Goldgar D; ; Beattie MS; Beckmann MW; Birrer MJ; Bogdanova N; Bolton KL; Brewster W; Brooks-Wilson A; Brown R; Butzow R; Caldes T; Caligo MA; Campbell I; Chang-Claude J; Chen YA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Despierre E; Doherty JA; Dörk T; Dürst M; Eccles DM; Ekici AB; Easton D; ; Fasching PA; de Fazio A; Fenstermacher DA; Flanagan JM; Fridley BL; Friedman E; Gao B; Sinilnikova O; ; Gentry-Maharaj A; Godwin AK; Goode EL; Goodman MT; Gross J; Hansen TV; Harnett P; Rookus M; ; Heikkinen T; Hein R; Høgdall C; Høgdall E; Iversen ES; Jakubowska A; Johnatty SE; Karlan BY; Kauff ND; Kaye SB; Chenevix-Trench G; ; Kelemen LE; Kiemeney LA; Kjaer SK; Lambrechts D; Lapolla JP; Lázaro C; Le ND; Leminen A; Leunen K; Levine DA; Lu Y; Lundvall L; Macgregor S; Marees T; Massuger LF; McLaughlin JR; Menon U; Montagna M; Moysich KB; Narod SA; Nathanson KL; Nedergaard L; Ness RB; Nevanlinna H; Nickels S; Osorio A; Paul J; Pearce CL; Phelan CM; Pike MC; Radice P; Rossing MA; Schildkraut JM; Sellers TA; Singer CF; Song H; Stram DO; Sutphen R; Lindblom A; ; Terry KL; Tsai YY; van Altena AM; Vergote I; Vierkant RA; Vitonis AF; Walsh C; Wang-Gohrke S; Wappenschmidt B; Wu AH; Ziogas A; Berchuck A; Risch HA;
    Clin Cancer Res; 2011 Jun; 17(11):3742-50. PubMed ID: 21385923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
    Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
    Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
    Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
    Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-expression forum: Decoy for microRNAs.
    Rigoutsos I; Furnari F
    Nature; 2010 Jun; 465(7301):1016-7. PubMed ID: 20577197
    [No Abstract]   [Full Text] [Related]  

  • 15. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
    Langevin SM; Christensen BC
    Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
    Kazmi HR; Chandra A; Kumar S; Satyam LK; Gupta A; Nigam J; Srivastava M; Mittal B
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2577-2583. PubMed ID: 27620744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.
    Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ
    Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study.
    D'Hooghe TM; Grechukhina O; Cho S; Fassbender A; O D; Peterse D; Weidhaas J; Taylor HS
    Gynecol Obstet Invest; 2019; 84(6):575-582. PubMed ID: 31185482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
    Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
    Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
    De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
    Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.